Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Marc LopezLaboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université U105, Institut Paoli-Calmettes, Label "Ligue Contre le Cancer", Marseille, France.ORCID 0000-0002-6573-633X
Emerence CrompotLaboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université U105, Institut Paoli-Calmettes, Label "Ligue Contre le Cancer", Marseille, France.ORCID 0000-0002-2761-6126
Emmanuelle JosselinTrGET Platform, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli-Calmettes, Marseille, France.ORCID 0000-0002-7647-9949
Anne FarinaICEP Platform, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli-Calmettes, Marseille, France.ORCID 0000-0002-6693-8590
Marion RubisICEP Platform, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli-Calmettes, Marseille, France.ORCID 0009-0004-0859-5958
Remy CastellanoTrGET Platform, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli-Calmettes, Marseille, France.ORCID 0000-0002-0152-985X
Joanna FaresEmergence Therapeutics SA, A Wholly Owned Subsidiary of Eli Lilly and Company, Marseille, France.ORCID 0009-0005-7287-7797
Maria WehbeEmergence Therapeutics SA, A Wholly Owned Subsidiary of Eli Lilly and Company, Marseille, France.ORCID 0000-0003-2900-2811
Yves ColletteTrGET Platform, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli-Calmettes, Marseille, France.ORCID 0000-0001-5359-7099
Emmanuelle CharafeICEP Platform, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli-Calmettes, Marseille, France.ORCID 0000-0002-0286-1299
Hatem A AzimEmergence Therapeutics SA, A Wholly Owned Subsidiary of Eli Lilly and Company, Marseille, France.ORCID 0000-0003-4865-3193
Florence LhospiceEmergence Therapeutics SA, A Wholly Owned Subsidiary of Eli Lilly and Company, Marseille, France.ORCID 0000-0002-2868-1181
Emilie MamessierLaboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université U105, Institut Paoli-Calmettes, Label "Ligue Contre le Cancer", Marseille, France.ORCID 0000-0002-3516-0093
François BertucciLaboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université U105, Institut Paoli-Calmettes, Label "Ligue Contre le Cancer", Marseille, France.ORCID 0000-0002-0157-0959
Jack ElandsEmergence Therapeutics SA, A Wholly Owned Subsidiary of Eli Lilly and Company, Marseille, France.ORCID 0009-0000-8703-3021
Xavier Préville *Emergence Therapeutics SA, A Wholly Owned Subsidiary of Eli Lilly and Company, Marseille, France.ORCID 0000-0002-1416-7405
Daniel Olive *Equipe Immunité et Cancer, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université U105, Institut Paoli-Calmettes, Marseille, France.ORCID 0000-0003-1299-4113
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
significanceETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors. · full record | OpenQuestion